Antoine Chéret
Hôpital Bicêtre · CH TOURCOING
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Antoine Chéret as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:16 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT02987530 · National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) InfectionANRS, Emerging Infectious Diseases · completed · HIV-1 Infection · principal investigator
- N/ANCT01269632 · Cohort of Young Adults Infected With HIV Since Birth or During ChildhoodFrench National Agency for Research on AIDS and Viral Hepatitis · completed · HIV Infection, Young Adult · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:16 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.N Engl J Med · 20151,339 citationsRCR 57.0
- Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.J Clin Oncol · 2006153 citationsRCR 3.6
- Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.J Acquir Immune Defic Syndr · 2016102 citationsRCR 4.2
- Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.J Antimicrob Chemother · 201594 citationsRCR 3.0
- Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.Lancet Infect Dis · 201562 citationsRCR 2.1
- Impact of early cART on HIV blood and semen compartments at the time of primary infection.PLoS One · 201727 citationsRCR 1.0
- Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.PLoS One · 201924 citationsRCR 1.1
- CD8 T-cells from most HIV-infected patients lack ex vivo HIV-suppressive capacity during acute and early infection.PLoS One · 201321 citationsRCR 0.5
- Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study.HIV Clin Trials · 200319 citationsRCR 0.6
- 13 citationsRCR 0.4